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We read with great interest the article “Adipose-derived 
mesenchymal stem cell therapy in the treatment of knee 
osteoarthritis: a randomized controlled trial” by Freitag 
et al., published in Regenerative Medicine last February 2019. 
We congratulate the authors for their work, which 
contains valuable clinical information to understand the 
effectiveness of the increasingly common treatment of knee 
osteoarthritis (OA) with adipose tissue-derived stem cells 
(ASCs). Indeed, literature reports fundamentally two types 
of treatment based on ASCs: stromal vascular fraction (SVF) 
(1,2) or in vitro expanded ASCs intra-articular injection (3,4).
This study reports the clinical results of knee OA 
treatment with in vitro expanded ASCs. We think that 
the selection of the patients based on Kellgren Lawrence 
grades II and III OA is the right choice since these patients 
can benefit of this treatment, delaying the time to surgical 
intervention of knee prosthesis as much as possible. In 
our experience the ASC infusion was previously shown to 
be most beneficial for this group of patients (2). A critical 
point in the patients’ eligibility criteria is the enrollment 
in the study of patients with unstable knees, which in our 
experience represents a potential contraindication. Patients 
affected by unstable knees or major axial deviation of the 
knee were the poorest responders in our series. We think 
that these patients might have a self-sustained inflammation 
more difficult to turn off. Moreover, we observed that 
when patients’ knees were washed with a saline solution 
before cell infusion the outcome was better than in non-
pre-washed ones. Thus, the authors should consider the 
presence of effusion of the knee as a possible hinderance 
against ASC cell adhesion in vivo (5). 
According to the authors, we believe that, despite the lack 
of a formal control/placebo, the results reported should be 
considered as a pilot study, and further research with more 
patients should be planned. The obtained results compared 
to untreated and to pre-operative evaluation suggest a 
decrease in symptoms and a better performance compared 
to the classical studies on the placebo effect with a sham 
knee arthroscopy (6). The real question to be challenged 
will be how long this procedure is going to be beneficial for 
the patients. Is this procedure able to revert a progressive 
primary degenerative OA? Are the injected ASCs directly 
responsible for regeneration? About this, recent literature 
infers that the beneficial effect of MSC infusion might be 
due to the indirect effect of the cell mediated interaction 
with local actors (chondrocytes and precursors, immune 
competent cells, etc.), either via direct cell to cell contact 
or via factors released locally (7,8). One of the major results 
of the ASC infusion is the inactivation of an inflammatory, 
self-sustaining phenomenon and not to the reconstruction 
of a novel cartilage layer (8). Moreover, in vivo studies in 
mouse OA models showed that autologous mesenchymal 
stem cells (MSCs) disappear from the injected joint in the 
early phases and that their beneficial effect might be due 
to an imprinting more than to the continuous presence of 
the MSCs (9). We believe that the biological composition 
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of the infused material is a major issue for future research 
in this field: understanding whether the treatment with 
expanded ASCs or SVF is better is fundamental for clinical 
practice. The role of the various precursors, lymphocytes 
and especially of the factors secreted by the infused cells is 
relevant for fully understanding the mechanism of action 
of the regenerative process and to select the active players 
leading to the relevant clinical results described. Further 
studies should be issued on this topic as well. 
Another particularly relevant aspect is the number of 
ASC infusion procedures, that should be effective. Indeed, 
this point acquires great interests for the future therapeutic 
developments. The authors provided data on the multiple 
infusion group which are not convincing for its beneficial 
effect in the long term compared to single infusion, even 
though MRI showed evidence of a measurable decrease 
in cartilage loss only in the two-injection group. In 
more general terms, at 1 year follow up the results of the 
single infusion are comparable to the ones obtained after 
two infusions. Moreover, the authors state that a third 
group, receiving 5 injections, was discontinued due to 
complications which are not fully described. Thus, some 
questions should be addressed, such as: “is one infusion 
enough to obtain long-term results in the reversion of 
knee OA?” “Are further infusions beneficial in the long-
term evolution of the disease, considering that one infusion 
obtains clinically relevant results maintained after one year 
from the procedure?” “Are we expecting complications after 
multiple infusions even though programmed on a yearly 
basis?”
To evaluate the effect of ASCs in the treatment of 
knee OA, the other major issue is the quantification of 
the regenerating effect on the affected cartilage using 
MRI. Many publications addressed this question without 
producing convincing information (10,11), due to technical 
reasons, such as the low resolution of the MRIs available 
to date or to the necessity of a longer observation periods 
to visualize the effect. Here, authors reported encouraging 
results where MRI serial studies showed a reduction or 
reversion of cartilage loss, but no clear evidence on a 
cartilage tissue improvement was documented with the 
methods used [MRI Osteoarthritis Knee Score (MOAKS)]. 
The author mention further studies to be performed on 
the quality of the cartilage using T2 mapping techniques, 
and we can say that we used this technique, without 
statistically relevant results in our studies (2). The indirect 
data obtained by MRI imaging such as periarticular bone 
marrow tissue quality, osteophytes, synovitis, meniscus, 
periarticular features such as cysts, etc., were not relevantly 
modified after MSC treatment. 
In contrast to clinical data, cell manufacturing process has 
been briefly described, thus we think that it should be useful 
to insert more details about the method adopted to obtain 
100×106 ASCs necessary for the intra-articular injection. 
Indeed, this is a high number of ASCs and it is not so easy 
to expand them into two in vitro passages only, as described 
by the authors. Moreover, what parameters were tested 
by the authors to evaluate the chondrogenic ability of the 
fresh and thawed ASCs in vitro? Could the cryopreservation 
process modify the differentiation ability of expanded 
ASCs? We previously demonstrated that cryopreservation 
of adipose tissue with dimethyl sulfoxide (DMSO) preserves 
the content of ASCs and their differentiating abilities (12), 
thus we are confident that also expanded ASCs of this study 
maintain their properties.
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